Survey of oncologists shows your medical affairs team may be reaching out too often
If doctors aren't warming up to your medical affairs team as much as you'd like, it may be time to take a step back. Our survey of 100 medical oncologists shows that many of them feel US medical affairs teams for leading NSCLC drugs are contacting them too often. With several teams competing closely, the right approach could make all the difference.
Find out how often you should be reaching out, and what else you can do to move your team ahead of its closest rivals in Medical Affairs Reputations: NSCLC (US) .
Comparing 12 major NSCLC treatments from Astellas Pharma, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, EMD Serono, Merck & Co., Novartis, Pfizer, and Roche, this report reveals:
- How oncologists rate your team overall, and on 12 key medical affairs services.
- Which medical affairs services are most important.
- How, and how often oncologists want to meet with your team.
- What you can do to improve your medical affairs services.
You're just a couple of clicks away from actionable information you can use to turn your team into one that doctors rely on.
- Is your team reaching out too often? Survey results show that most teams may be contacting doctors more often than they would like. Find out how often is too often.
- Competition is close at every level: Rated for overall quality of interactions, teams at the top, middle and bottom of the market are within just a few points of one or more rivals.
- All teams are turning in a solid performance: EdgeMap performance ratings show that, while the top teams have a slight edge, every team earns a moderately high score from doctors.
- Satisfaction scores vary: EdgeMap satisfaction scores are moderately high overall, but a handful of teams outscore the rest on all 12 surveyed medical affairs roles.
- Doctors want actionable information: The five most important roles for medical affairs teams all revolve around providing information doctors can use to make better treatment decisions.
- There are many other ways teams can improve: More than 80 percent of surveyed doctors had specific suggestions for improving information provision, communication, or continuing medical education (CME) support.
Insight into Medical Affairs Teams for These NSCLC Treatments
- Avastin (bevacizumab; Roche)
- Cyramza (ramucirumab; Eli Lilly)
- Gilotrif (afatinib; Boehringer Ingelheim)
- Iressa (gefitinib; AstraZeneca)
- Keytruda (pembrolizumab; Merck & Co.)
- Opdivo (nivolumab; Bristol-Myers Squibb)
- Portrazza (necitumumab; Eli Lilly)
- Tagrisso (osimertinib; AstraZeneca)
- Tarceva (erlotinib; Roche/Astellas Pharma)
- Tecentriq (atezolizumab; Roche)
- Xalkori (crizotinib; Pfizer/EMD Serono)
- Zykadia (ceritinib; Novartis)
An Expert-designed Competitive View of Your Medical Affairs Team
Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 12 medical affairs teams-answering important questions like:
- How, and how often are they using your medical affairs team?
- What services do they consider most important?
- How often should you contact them? What channels are best?
Does your medical affairs team deliver?
- How memorable are your team's interactions with doctors?
- How do doctors rank your team for performance and satisfaction in 12 key areas?
- How does your team compare to the competition-in each area, and overall?
What needs improvement?
- Are you delivering the services that are most important to doctors?
- Where do you need to improve?
- How can your team enhance its services?
Based on Interviews with Practicing Doctors
We surveyed 100 US medical oncologists, chosen from the largest community of validated physicians in the world.
- Have been practicing for between 3 and 35 years
- See at least 5 patients with NSCLC in a typical month
- Devote at least 50% of their time to direct patient care
- Have interacted with at least one listed product's medical affairs team in the past 6 months.
We conducted the survey between February 2nd and 8th, 2017.
Find out what 100 US dermatologists think of your medical affairs team.